Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone Metastasis

NCT02097303 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone

Sponsor

Carolina Research Professionals, LLC

Collaborators

[object Object]